- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
OVD dual pack gets FDA approval
Abbott has received FDA approval for its Healon Duet Dual Pack OVD, which includes Healon and Healon EndoCoat OVDs in separate sterile trays.
Abbott Park, IL-Abbott has received FDA approval for its Healon Duet Dual Pack ophthalmic viscosurgical device (OVD). The pack includes Healon (high viscosity) and Healon EndoCoat (dispersive) OVDs in separate sterile trays within one package to allow physicians to streamline their cataract surgery setup.
“The U.S. approval of the [dual pack] adds to Abbott’s reliable portfolio of OVD offerings that have been used for more than 25 years worldwide,” said Murthy Simhambhatla, senior vice president, Abbott Medical Optics. “Now delivered together, [the two OVDs] offer the cataract surgeon outstanding protection, control, clarity, and ease-of-use during each step of the procedure.”
To learn more about Abbott's family of Healon OVDs, visit www.abbottmedicaloptics.com.
For more articles in this issue of Ophthalmology Times eReport, click here.
